{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:21:26Z","timestamp":1792844486798,"version":"4.5.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Belzutifan is a HIF-2\u0251 inhibitor approved for the treatment of tumors in von Hippel-Lindau (VHL) syndrome and sporadic metastatic clear cell renal cell carcinoma (spRCC) in the refractory setting. The efficacy and side effects of belzutifan are well-documented from clinical trials; however, real-world data examining the incidence and management of adverse events (AEs) are lacking. Our study aims to describe the AE profiles of belzutifan in spRCC and VHL populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective analysis was conducted at Vanderbilt University Medical Center assessing patients who received belzutifan monotherapy. Primary endpoints were the incidence of anemia and hypoxia. Secondary endpoints included time to onset of anemia and hypoxia, as well as management strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-four patients were identified with either spRCC (n\u2009=\u200922) or VHL syndrome (n\u2009=\u200922). Patients with spRCC were older than VHL patients (median 67 vs 41\u2009years) and had higher rates of chronic kidney disease (36.4% vs 4.5%) and prior nephrectomy (77.3% vs 40.9%). The spRCC patients had a median follow-up time of 3.8\u2009months vs 26.8\u2009months in VHL patients. Any-grade anemia occurred in the majority of spRCC and VHL patients (81% and 95.5%, respectively) with a median time of 25\u2009days in spRCC patients and 77\u2009days in VHL patients. While no patient with VHL experienced grade 3 anemia, 41% of spRCC patients developed grade \u22653 anemia. In spRCC, grade \u22653 hypoxia developed in 54.5% and for VHL patients, grade 3 hypoxia occurred in 9%. Median time to grade \u22653 hypoxia was 29\u2009days (range 12-123) in spRCC patients and 225\u2009days (range 105-345) in VHL patients. Supplemental oxygen was required in 52.5% of spRCC patients and 9.5% in VHL patients. Treatment discontinuation due to AEs occurred in 50% of spRCC patients and 13.6% of VHL patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The time to onset and severity of belzutifan AEs may differ between patients with VHL syndrome and spRCC. These findings suggest the need for a patient-centered approach to monitor and manage toxicity based on disease setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf274","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:29:02Z","timestamp":1757345342000},"source":"Crossref","is-referenced-by-count":4,"title":["The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-7898","authenticated-orcid":false,"given":"Aaron Jacob","family":"Winer","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3205-3799","authenticated-orcid":false,"given":"Paulo Siqueira","family":"do Amaral","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth G","family":"Ryan","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan A","family":"Lambrecht","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Lan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Biostatics, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2212-080X","authenticated-orcid":false,"given":"Brian I","family":"Rini","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4616-6140","authenticated-orcid":false,"given":"Kathryn E","family":"Beckermann","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center , Nashville, TN 37232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"2025093015120610900_oyaf274-B1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","article-title":"Von Hippel-Lindau disease","volume":"2","author":"Kaelin","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"2025093015120610900_oyaf274-B2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet"},{"key":"2025093015120610900_oyaf274-B3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"key":"2025093015120610900_oyaf274-B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The cancer genome atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat Rev Urol"},{"key":"2025093015120610900_oyaf274-B5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"2025093015120610900_oyaf274-B6","doi-asserted-by":"publisher","first-page":"10515","DOI":"10.1200\/JCO.2023.41.16_suppl.10515","article-title":"Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan","volume":"41","author":"Chidharla","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025093015120610900_oyaf274-B7","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/jcph.2459","article-title":"Exposure\u2013response analyses for belzutifan to inform dosing considerations and labeling","volume":"64","author":"Marathe","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"2025093015120610900_oyaf274-B8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-020-1093-z","article-title":"Targeting the HIF2\u2013VEGF axis in renal cell carcinoma","volume":"26","author":"Choueiri","year":"2020","journal-title":"Nat Med"},{"key":"2025093015120610900_oyaf274-B9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2024.08.2338","article-title":"Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma","volume":"35","author":"Agarwal","year":"2024","journal-title":"Ann Oncol"},{"key":"2025093015120610900_oyaf274-B10","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel\u2013lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"2025093015120610900_oyaf274-B11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced Renal-Cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"2025093015120610900_oyaf274-B12","doi-asserted-by":"publisher","first-page":"113434","DOI":"10.1016\/j.ejca.2023.113434","article-title":"Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort","volume":"196","author":"Jonasch","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025093015120610900_oyaf274-B13","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2025093015120610900_oyaf274-B14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/jcmm.13319","article-title":"Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition","volume":"22","author":"Olmos","year":"2018","journal-title":"J Cell Mol Med"},{"key":"2025093015120610900_oyaf274-B15","author":"FDA Belzutifan Label"},{"key":"2025093015120610900_oyaf274-B16","doi-asserted-by":"publisher","first-page":"S1016","DOI":"10.1016\/j.annonc.2024.08.1788","article-title":"1695P phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)","volume":"35","author":"Vaishampayan","year":"2024","journal-title":"Ann Oncol"},{"key":"2025093015120610900_oyaf274-B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1081\/DMR-120023681","article-title":"PM frequencies of major CYPs in Asians and Caucasians","volume":"35","author":"Mizutani","year":"2003","journal-title":"Drug Metab Rev"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf274\/64222333\/oyaf274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf274\/64222333\/oyaf274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf274\/64222333\/oyaf274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:12:14Z","timestamp":1759259534000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf274\/8249253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf274","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,9,1]]},"article-number":"oyaf274"}}